Edition:
United States

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

49.22USD
22 Sep 2017
Change (% chg)

$0.16 (+0.33%)
Prev Close
$49.06
Open
$49.17
Day's High
$49.44
Day's Low
$49.00
Volume
248,126
Avg. Vol
411,891
52-wk High
$49.44
52-wk Low
$30.90

Latest Key Developments (Source: Significant Developments)

Health Canada approves Novo Nordisk's Tresiba, a new basal insulin for type 1 and 2 diabetes
Monday, 28 Aug 2017 08:30am EDT 

Aug 28 (Reuters) - Novo Nordisk A/S :Health Canada approves Tresiba®, a new basal insulin for type 1 and 2 diabetes.‍Novo Nordisk Canada Inc - Health Canada has approved Tresiba​.  Full Article

Novo Nordisk diabetes drug Victoza reduces risk of heart attacks
Monday, 28 Aug 2017 08:01am EDT 

Aug 28 (Reuters) - NOVO NORDISK :DIABETES DRUG VICTOZA REDUCES THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN PEOPLE WITH TYPE 2 DIABETES WITH OR WITHOUT PRIOR EVENTS.A NEW ANALYSIS OF THE LEADER TRIAL SHOWS THAT VICTOZA REDUCED THE RISK OF MAJOR CARDIOVASCULAR (CV) EVENTS IN PEOPLE WITH TYPE 2 DIABETES AT HIGH CV RISK, IRRESPECTIVE OF THEIR HISTORY OF HAVING A HEART ATTACK AND/OR STROKE OR NOT HAVING ANY OF THESE EVENTS, WHEN COMPARED TO PLACEBO.THE POST-HOC ANALYSIS WAS PRESENTED ON MONDAY AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) ANNUAL CONGRESS IN BARCELONA, SPAIN..VICTOZA REDUCED THE RISK OF MAJOR CV EVENTS (NON-FATAL HEART ATTACK, NON-FATAL STROKE AND CV DEATH) BY 16 PERCENT IN PEOPLE WHO HAD ALREADY EXPERIENCED A HEART ATTACK AND/OR STROKE WHEN THE TRIAL STARTED.A NON-SIGNIFICANT 11 PERCENT RISK REDUCTION WAS ACHIEVED WITH VICTOZA TREATMENT IN PEOPLE WHO HAD NOT EXPERIENCED A PRIOR HEART ATTACK AND/OR STROKE..  Full Article

U.S. FDA approves CV label for Novo's diabetes drug Victoza‍​
Friday, 25 Aug 2017 11:26am EDT 

Aug 25 (Reuters) - U.S. Food and Drug Administration::Approved new indication for Victoza (liraglutide) to reduce risk of major adverse cardiovascular events in adults with type 2 diabetes, cv disease‍​.  Full Article

Novo Nordisk says Semaglutide superior to Dulaglutide in sustain 7 trial
Wednesday, 16 Aug 2017 02:02pm EDT 

Aug 16 (Reuters) - Novo Nordisk A/S :Novo nordisk says semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in sustain 7.Novo nordisk says in trial, semaglutide demonstrated a safe and well-tolerated profile consistent with results from sustain programme.  Full Article

Novo Nordisk puts Camilla Sylvest in charge of commercial strategy, corporate affairs
Tuesday, 15 Aug 2017 02:00am EDT 

Aug 15 (Reuters) - NOVO NORDISK SAYS:CAMILLA SYLVEST, SENIOR VICE PRESIDENT IN CHARGE OF NOVO NORDISK'S OPERATIONS IN REGION CHINA, HAS BEEN APPOINTED EXECUTIVE VICE PRESIDENT IN CHARGE OF COMMERCIAL STRATEGY AND CORPORATE AFFAIRS.AT THE HELM OF THIS NEW UNIT SHE WILL BE OVERALL RESPONSIBLE FOR THE COMPANY'S CORPORATE FUNCTIONS WITHIN MARKETING, MARKET ACCESS, STRATEGY, COMMUNICATION, STAKEHOLDER RELATIONS AND SUSTAINABILITY..DOUG LANGA, SENIOR VICE PRESIDENT, HEAD OF NORTH AMERICA OPERATIONS AND PRESIDENT OF NOVO NORDISK INC, IS PROMOTED TO EXECUTIVE VICE PRESIDENT. HIS RESPONSIBILITIES REMAIN UNCHANGED..  Full Article

Novo Nordisk CEO says won't provide explicit guidance on price
Wednesday, 9 Aug 2017 02:00am EDT 

Aug 9 (Reuters) - NOVO NORDISK A/S :CEO SAYS NOVO NORDISK DO NOT INTEND TO PROVIDE EXPLICIT GUIDANCE ON PRICE IN THE FUTURE."GOING FORWARD, WE DO NOT INTEND TO GIVE EXPLICIT GUIDANCE ON THE PRICE DEVELOPMENT AS WE BELIEVE COMMENTING ON PRICE IN ISOLATION DOES NOT PROVIDE A COMPLETE PICTURE FOR THE OUTCOME OF FORMULARY NEGOTIATIONS," CEO LARS FRUERGAARD SAID ON A CONFERENCE CALL. .  Full Article

Novo Nordisk Q2 beats forecast; sees U.S. prices lower in 2018
Wednesday, 9 Aug 2017 01:38am EDT 

Aug 9 (Reuters) - NOVO NORDISK SAYS:INCREASED REPORTED OPERATING PROFIT BY 8% IN THE FIRST SIX MONTHS OF 2017.EXPECTS AVERAGE U.S. PRICES AFTER REBATES TO BE LOWER COMPARED WITH LEVELS IN 2017, PREDOMINANTLY DRIVEN BY BASAL INSULIN SEGMENT.SAYS MARKET ACCESS FOR NOVO NORDISK'S KEY PRODUCTS IS, HOWEVER, EXPECTED TO REMAIN BROADLY UNCHANGED COMPARED TO 2017.Q2 OPERATING PROFIT 13,386 MILLION DKK VERSUS 12,674 MILLION DKK SEEN IN REUTERS POLL.CEO SAYS WE ARE WELL ON TRACK TO DELIVER ON OUR TARGETS FOR 2017.H1 SALES 57.1 BILLION DKK VERSUS 56.75 BILLION DKK SEEN IN REUTERS POLL.H1 NET PROFIT 20.1 BILLION DKK VERSUS 19.83 BILLION DKK SEEN IN REUTERS POLL.FINANCIAL OUTLOOK FOR 2017 HAS BEEN UPDATED AND SALES GROWTH MEASURED IN LOCAL CURRENCIES IS NOW EXPECTED TO BE IN RANGE OF 1% TO 3% COMPARED WITH PREVIOUS RANGE OF 0% TO 3%.SAYS OPERATING PROFIT GROWTH MEASURED IN LOCAL CURRENCIES IS NOW EXPECTED TO BE IN RANGE OF 1% TO 5% COMPARED WITH PREVIOUS RANGE OF -1% TO 3%.A NEGATIVE CURRENCY IMPACT OF 3 PERCENTAGE POINTS IS NOW EXPECTED.H1 OPERATING PROFIT 26.9 MILLION DKK.SAYS BOARD OF DIRECTORS HAS APPROVED AN INTERIM DIVIDEND FOR 2017 OF DKK 3.00 PER SHARE OF DKK 0.20 THAT WILL BE PAID IN AUGUST 2017.CEO SAYS ALTHOUGH FORMULARY NEGOTIATIONS IN USA REFLECT TOUGH COMPETITIVE ENVIRONMENT, WE REMAIN CONFIDENT THAT OUR LONG-TERM FINANCIAL GROWTH TARGETS ARE ACHIEVABLE.  Full Article

Novo Nordisk says trial shows semaglutide helps to lose weight
Friday, 23 Jun 2017 10:45am EDT 

June 23 (Reuters) - Novo Nordisk :Reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial.Says in the trial, 957 people with obesity were randomised to treatment with doses of semaglutide between 0.05 to 0.4 mg/day or placebo.Says from a mean baseline weight of around 111 kg and a body mass index of approximately 39 kg/m(2), a weight loss up to 17.8 kg was observed after 52 weeks of treatment with semaglutide.Says this corresponded to an estimated 13.8% weight loss compared to the weight loss of 2.3% achieved by diet, exercise and placebo alone, with all treatment arms adjusted for people discontinuing treatment in the study .Says expects phase 3 programme with semaglutide to begin in 2018.  Full Article

Novo Nordisk: EMA committee issues positive opinion for Victoza label update
Friday, 23 Jun 2017 07:40am EDT 

June 23 (Reuters) - Novo Nordisk A/S :The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza .The update is based on the results from the LEADER trial which investigated the long-term effects of Victoza in people with type 2 diabetes, at high risk of major cardiovascular events.The CHMP positive opinion for Victoza(®) is now referred to the European Commission, which grants approval in the EU, for final action on the proposed indication.Novo Nordisk expects to receive the European Commission decision for the Victoza label update in the third quarter of 2017.  Full Article

Novo Nordisk says announced that CHMP has endorsed an update of EU label for Saxenda
Thursday, 22 Jun 2017 02:20pm EDT 

June 22 (Reuters) - Novo Nordisk :Novo Nordisk says announced that chmp, under european medicines agency , has endorsed an update of eu label for saxenda.Expects feedback from ema on Victoza application shortly.  Full Article

BRIEF-Calidus enters joint venture with Novo Resources

* Consideration to Novo is 20 million shares & expenditure commitment of $2 million over 3 years